Ask AI
IDST for SCLC
Interactive Treatment Decision Tool for SCLC: Expert Guidance on Treatment

Released: November 26, 2025

References

ACR Appropriateness Criteria Expert Panel on Neurologic Imaging. Brain tumors (follow-up/surveillance imaging considerations). J Am Coll Radiol. 2025;22(5 Suppl):S108-S135.

Bogart JA, Wang X, Masters GA, et al. High-dose once-daily thoracic radiotherapy in limited-stage small-cell lung cancer: CALGB 30610 (Alliance)/RTOG 0538. J Clin Oncol. 2023;41:2394-2402.

Brown PD, Gondi V, Pugh S, et al. Hippocampal avoidance during whole-brain radiotherapy plus memantine for patients with brain metastases (NRG-CC001): a phase 3 randomized trial. J Clin Oncol. 2020;38:1019-1029.

Cheng Y, Spigel DR, Cho BC, et al. Durvalumab after chemoradiotherapy in limited-stage small-cell lung cancer. N Engl J Med. 2024;391:1313-1327.

Chun SG, Welsh JW. Are we finally ready to implement twice-daily thoracic radiation for LS-SCLC? Int J Radiat Oncol Biol Phys. 2024;[Epub ahead of print].

Durvalumab [prescribing information]. Wilmington, DE: AstraZeneca; 2025.

Johnson DR, Brown PD, Gondi V. Sustained preservation of cognition with hippocampal-avoidance WBRT plus memantine: final NRG-CC001 report. Int J Radiat Oncol Biol Phys. 2023;116:e1-e3.

Kalemkerian GP, Khurshid H, Ismaila N. Systemic therapy for small cell lung cancer: ASCO Guideline Rapid Recommendation Update. J Clin Oncol. 2025;43:101-105.

National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology: small cell lung cancer. v.2.2026. nccn.org. Accessed November 21, 2025.

Takahashi T, Yamanaka T, Seto T, et al. Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18:663-671.

Turrisi AT, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 1999;340:265-271.

Vogelbaum MA, Brown PD, Messersmith H, et al. Treatment for brain metastases: ASCO-SNO-ASTRO guideline. J Clin Oncol. 2021;39:3989-4024.

Access to and use of this Interactive Decision Support Tool titled, “Interactive Treatment Decision Tool for SCLC: Expert Guidance on Treatment” is provided subject to the following terms and conditions. PLEASE READ THESE TERMS CAREFULLY.

This Interactive Decision Support Tool is designed to is a unique, dynamic online resource that provides clear expert guidance on management decisions for individual patients with small-cell lung cancer (SCLC). In total, 5 experts are presented with myriad possible patient and disease characteristics combinations and asked to provide their treatment selection for each scenario. 

The material published by Decera Clinical Education reflects the views of the reviewers or authors, not those of Decera Clinical Education or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the FDA. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Although the information contained in the “Interactive Treatment Decision Tool for SCLC: Expert Guidance on Treatment” Interactive Decision Support Tool has been produced and processed from sources believed to be reliable, no warranty, expressed or implied, is made regarding the accuracy, adequacy, completeness, legality, reliability, or usefulness of any information. This disclaimer applies to both the isolated and aggregate uses of the information. Decera Clinical Education provides this information on an as-is basis. This disclaimer applies to all material published by Decera Clinical Education including but not limited to medical information or opinions. All warranties of any kind, expressed or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, freedom from contamination by computer viruses, and noninfringement of proprietary rights are disclaimed.

Any trademarks are the property of respective companies.

© 2025 Decera Clinical Education. All rights reserved.

Program Content